Baseline characteristics of patients and of HCs and study drug exposure and compliance throughout the study.

aFor the difference between groups from the Student’s t-test.bFor the difference between groups from Fisher’s exact test.cIncludes one of Hispanic ethnicity, all other subjects were not Hispanic.dPatients reported the same number of relapses for the past 24 months.eCompliance was calculated at study visits using subject diaries and returned drug. Exposure was calculated from compliance.BMI; body mass index; DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; HC, healthy control; IFN β-1a, interferon beta-1a; IV Ig, intravenous immunoglobulin; MS, multiple sclerosis; SC, subcutaneous; SD, standard deviation; tiw, three times weekly.

a. 基于学生t检验（Student’s t-test）得到组间差异。
b. 基于Fisher确切概率法（Fisher’s exact test）得到组间差异。
c. 受试人群中包含西班牙裔个体，其余所有受试者均非西班牙裔。
d. 受试者自述其过去24个月内的复发次数相同。
e. 依从性通过受试者日记与回收药物在研究访视时进行计算；药物暴露量则基于依从性结果计算得到。
BMI：体重指数（body mass index）；DMD：疾病修饰药物（disease-modifying drug）；EDSS：扩展残疾状态量表（Expanded Disability Status Scale）；HC：健康对照（healthy control）；IFN β-1a：干扰素β-1a（interferon beta-1a）；IV Ig：静脉注射免疫球蛋白（intravenous immunoglobulin）；MS：多发性硬化（multiple sclerosis）；SC：皮下注射（subcutaneous）；SD：标准差（standard deviation）；tiw：每周三次（three times weekly）